Also known as: GnRH · Gonadotropin-releasing hormone · Factrel · Lutrepulse · LHRH
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH) that stimulates the pituitary to release LH and FSH, maintaining natural testosterone production and testicular function. It is widely used alongside TRT to prevent testicular atrophy and preserve fertility.
Gonadorelin is a synthetic decapeptide identical to endogenous GnRH. It stimulates the anterior pituitary to release luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn maintain endogenous testosterone production and spermatogenesis. Pulsatile administration is critical — continuous exposure leads to receptor downregulation and suppressed LH/FSH.
Gonadorelin binds GnRH receptors on anterior pituitary gonadotroph cells, triggering IP3/DAG signalling and calcium influx, which stimulates LH and FSH release. Pulsatile dosing (every 90–120 minutes, or twice-weekly subcutaneous) mimics hypothalamic pulse frequency and maintains pituitary sensitivity.
Gonadorelin degrades rapidly at room temperature after reconstitution — refrigerate and use within 7 days. Very short half-life means twice-weekly SC injections are the minimum effective frequency. Generally well tolerated; injection-site reactions possible. Preferred over hCG by some TRT physicians for its physiological pulsatile mechanism and lack of oestradiol stimulation.
Gonadorelin is used as an ongoing TRT adjunct rather than in cycles. Discontinue only when TRT is stopped to allow full HPG axis recovery. For fertility-focused protocols, may be used as a bridge during TRT taper.
Used in TRT protocols to preserve testicular volume and sperm production. Typical research dose: 100–250 mcg subcutaneous twice weekly. Must be stored carefully — degrades rapidly at room temperature after reconstitution. Preferred over hCG by some clinicians for its more physiological pulsatile mechanism.
Ask anything about Gonadorelin — mechanisms, dosing protocols, interactions, or research comparisons.
Bremelanotide (PT-141 / Vyleesi) is an FDA-approved melanocortin receptor agonist used for hypoactive sexual desire diso…
Palopegteriparatide (Yorvipath, TransCon PTH) is a long-acting PTH(1-34) prodrug that slowly releases free teriparatide…